Melazyme, founded by two Perfect Day alumni, has raised $2 million to scale precision-fermented melanin and brazzein — signaling a shift toward high-value molecules over commodity dairy substitutes.
Two former Perfect Day executives have closed a $2 million seed round for Melazyme, a precision fermentation startup betting that the next phase of the technology lies in high-value specialty molecules rather than dairy substitutes. The round was led by SeaX Ventures, with Stellaris Venture Partners and Plug and Play Ventures participating.
The conventional narrative around precision fermentation has centered on replacing animal commodities: milk proteins, egg whites, collagen. Melazyme is pointing somewhere else entirely: melanin and sweet proteins, with applications ranging from cosmetics to environmental remediation.
Founded in 2025 by Perumal Gandhi and Bonney Oommen, former Perfect Day executives, the company is using engineered microbes to produce melanin at over 99% purity, compared with 70–80% purity from cuttlefish blood extraction and roughly 75% from chemical synthesis.
The resulting powder is being positioned across cosmetics, UV protection, functional coatings, filtration, and rare-earth element recovery. Near-term commercial activity sits squarely in cosmetics, where a specialised melanin precursor binds to hair keratin and restores natural colour without ammonia or oxidative dyes.
The company's second track is brazzein, a heat-stable sweet protein from the West African Oubli fruit that is 500 to 2,000 times sweeter than sucrose. The opportunity is sized against a global high-intensity sweetener market projected to surpass $30 billion by the end of the decade, currently dominated by aspartame, sucralose, and stevia derivatives. Brazzein's appeal is its clean sugar-like profile and stability under heat and low pH — properties that have eluded stevia and monk fruit in baked and acidic applications. Competitors including Oobli (which secured FDA GRAS status for its brazzein in 2023) and Magellan Life Sciences are already moving product, but Melazyme is wagering that yield economics at fermentation scale will determine who wins the category rather than first-mover status.
SeaX managing partner Kid Parchariyanon framed the bet in generational terms, highlighting the founders' experience in building and scaling precision fermentation companies and noting that Melazyme focuses on molecules where fermentation provides immediate and differentiated value.
The strategic pivot is worth pausing on. Perfect Day spent years proving that animal-free whey was technically possible and ran into the brutal economics of competing with commodity dairy on price. Melazyme's founders appear to have learned the lesson. Melanin at pharmaceutical-grade purity isn't competing with commodity dairy. It's competing with extraction processes that are messy, low-yield, and capacity-constrained.
That shift matters for the broader plant-based and biotech space. The question isn't whether fermentation can replicate animal molecules. It's whether the technology gets deployed against problems where it has a structural advantage — supply consistency, tunability, lower environmental load — rather than commodity races it tends to lose. A $2 million seed is small money. The thesis behind it is not.
